"In November, 2011, Viral Genetics announced that a patent under which it is exclusively licensed will be granted for using a compound known as DCA to treat cancer. DCA (dichloroacetic acid) has emerged as a compound that accelerates the destruction of tumors without the deleterious and debilitating side effects associated with chemotherapy or radiation. This is the first patent granted for the use of DCA to treat cancer, and represents a significant milestone in the Company's growth.

Since filing the application, other companies and research entities, both in the US and internationally, have also done much work to validate and unlock the value inherent in utilizing DCA as a therapeutic agent. Over the last four years, extensive validating research has been performed that documents DCA as a potentially powerful cancer treatment. Dr. Newell Rogers is one of the scientific pioneers suggesting that agents, including DCA, that disrupt tumor specific metabolic pathways, will have value as novel cancer drugs and, as such, she is the first researcher to have a patent granted on its use in the battle against cancer.

Viral Genetics has been strategically accumulating a significant and valuable portfolio of intellectual property rights around Dr. Newell's core metabolic disruption science. This patent, and many others that will be granted, are expected to continue to create value for the Company’s shareholders. In concert with our legal team, Viral Genetics is setting in place the licensing and revenue strategy for the Company from this IP portfolio."

http://www.zacks.com/stock/news/66740/Viral+Genetics+Has+Mad...